Tempus ECG-Low EF vs Rhythm360
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary goal is to quickly screen and identify patients aged 40 or older who may be at risk of heart failure, based on a standard 12-lead ECG. This tool is ideal for clinical diagnostic settings where a rapid, AI-powered binary assessment of low LVEF risk can aid in prioritizing further evaluation.
View Tempus ECG-Low EF →Choose Rhythm360 if…
Choose Rhythm360 if your practice requires a comprehensive, integrated platform to manage cardiac monitoring data from diverse devices and streamline patient care for conditions like hypertension, heart failure, and arrhythmias. This solution is best suited for clinics seeking to reduce alert fatigue, automate administrative tasks like billing, and gain actionable, AI-driven insights across a broad patient population with existing cardiac conditions.
View Rhythm360 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | Rhythm360 |
|---|---|---|
| Pricing | Unknown | Flexible pricing model that scales with clinic size and platform usage. |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Cloud-based SaaS platform |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Unknown |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Rhythm360Tool B (Rhythm360) offers a more comprehensive and flexible user experience through its cloud-based SaaS platform, bi-directional EHR integration, and a HIPAA-compliant mobile application. This allows for seamless data aggregation from various devices and accessibility for clinicians across different settings. Tool A (Tempus ECG-Low EF) is integrated into existing workflows but lacks the broader platform capabilities and mobile access.
Clinical Value
Rhythm360While Tool A (Tempus ECG-Low EF) provides specific, FDA-cleared AI for early detection of low LVEF from ECGs, Tool B (Rhythm360) offers broader clinical value by unifying data, reducing alert fatigue, and providing actionable insights across hypertension, heart failure, and rhythm management. Its predictive algorithms for heart failure and GDMT optimization address multiple critical cardiac conditions and improve workflow efficiency. Tool B's comprehensive approach to managing multiple conditions and improving workflow efficiency offers substantial clinical value.
Pricing & Value
Rhythm360Tool B (Rhythm360) provides a flexible, scalable SaaS pricing model and explicitly mentions automated CPT code documentation and billing, which directly contributes to revenue generation and operational efficiency for clinics. Tool A (Tempus ECG-Low EF) only states 'contact vendor' for pricing, offering no transparency or clear value proposition regarding cost-effectiveness. Despite Tool B's potential 'premium pricing,' its clear value-add in billing and scalability makes it a stronger contender.
Enterprise Readiness
Rhythm360Tool B (Rhythm360) demonstrates superior enterprise readiness with its cloud-based SaaS platform, extensive bi-directional EHR integrations (Epic, Cerner, Athenahealth, etc.), and vendor-neutral data aggregation across all major OEM cardiac devices. This makes it highly adaptable to diverse existing healthcare IT infrastructures. Tool A (Tempus ECG-Low EF) integrates into workflows but does not detail the same breadth of integration capabilities.
Innovation
Tempus ECG-Low EFTool A (Tempus ECG-Low EF) presents a significant innovation with its FDA-cleared AI algorithm that analyzes standard 12-lead ECGs to detect signs of low LVEF, a critical and often underdiagnosed condition. This represents a novel application of AI for early, non-invasive diagnostic screening. While Tool B (Rhythm360) is innovative in its data aggregation and workflow optimization, Tool A's specific diagnostic breakthrough using a widely available test stands out.
Support & Docs
Rhythm360Tool B (Rhythm360) explicitly offers optional 24/7/365 oversight by certified cardiac technicians (CCTs), indicating a robust and dedicated support structure. Tool A (Tempus ECG-Low EF) provides no information regarding its support offerings or documentation. Therefore, Tool B is the clear winner in this dimension due to its transparent and comprehensive support option.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | Rhythm360 |
|---|---|---|
| Product Name | Tempus ECG-Low EF | Rhythm360 |
| Company | Tempus AI | RhythmScience |
| Primary Function/Description | AI software analyzing 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure, providing a binary output to aid clinicians in further evaluation. | AI-powered integrated platform that unifies cardiac monitoring data from various devices, providing actionable insights for hypertension, heart failure, and rhythm management, and reducing alert fatigue. |
| Target Condition/Detection | Low Left Ventricular Ejection Fraction (LVEF u226440%) | Hypertension, heart failure, and rhythm management |
| Key Input Data | Resting, non-ambulatory 12-lead ECG recordings | Cardiac monitoring data from various devices (vendor-neutral aggregation) |
| EHR Integration Specifics | Not specified | Bi-directional EHR integration (Epic, Cerner, Athenahealth, eClinicalWorks, GreenwayHealth, GE Centricity) |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Rhythm360.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or Rhythm360
Backers
Who funded each tool's parent company.